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arco A. Costa, MD, PHD, FACC*
acksonville, Florida; and Madrid, Spain
OBJECTIVES The aim of this research was to evaluate the plaque prolapse (PP) phenomenon after
bare-metal (BMS) and drug-eluting stent (DES) implantation in patients with diabetes
mellitus using 3-dimensional volumetric intravascular ultrasound (IVUS).
BACKGROUND Plaque prolapse has been observed in up to 22% of patients treated with BMS. Diabetic
patients have a larger atherothrombotic burden and may be more prone to have PP. However,
the incidence of PP and its clinical impact after DES implantation is unknown.
METHODS Three-dimensional IVUS was performed after intervention and at 9-month follow-up in 168
patients with diabetes (205 lesions) treated with bare BX Velocity stents ((BX Velocity/Sonic,
Cordis, Johnson & Johnson) (BMS, n 65), sirolimus-eluting stents (Cypher, Cordis) (SES,
n  69), and paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, Massachusetts)
(PES, n  71). Intravascular ultrasound data at the sites of PP were compared with stented
segments without PP in each lesion. Outcomes were evaluated at 9- and 12-month follow-up.
RESULTS There were 42 sites of PP (BMS  11, SES  11, PES  20, p  NS) in 34 stented
segments of 205 (16.6%) lesions. Plaque prolapse was more frequent in the right coronary
artery and in chronic total occlusion lesions. Post-procedure PP volume was 1.95 mm3 in
BMS, 2.96 mm3 in SES, and 4.53 mm3 in PES. At follow-up, tissue volume increased at PP
sites in both BMS and PES, but not after SES. Neointimal proliferation was similar between
PP and non-PP sites. Stent thrombosis and restenosis rates were similar between PP and
non-PP lesions.
CONCLUSIONS The incidence of PP after implantation of new generation tubular stents in patients with
diabetes remains high. Drug-eluting stent implantation was not associated with increased risk
of PP. Plaque prolapse was not associated with stent thrombosis or increased neointimal
proliferation. (J Am Coll Cardiol 2006;48:1139–45) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.050Cardiology Foundation
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ingiography is limited to detect prolapse or herniation of
theromatous plaque material into the coronary lumen
hrough the stent struts (1). However, plaque prolapse
PP) is not a rare phenomenon and has been detected
requently by intravascular ultrasound (IVUS). Up to 22%
f patients treated with bare-metal stents (BMS) may
evelop PP (2). When PP occurs, cardiologists usually
ace the dilemma of further balloon dilation or additional
tent deployment to improve lumen dimensions or pre-
ent complications such as thrombosis and restenosis.
laque prolapse may generate further clinical uncertainty
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rants from the Japan Heart Foundation/Bayer Yakuhin Research Grant Abroad. Dr.
osta has received speaker fees from Cordis, Johnson & Johnson.u
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ccepted May 15, 2006.fter deployment of drug-eluting stents (DES), because
f their cost and potential risk of thrombosis (3). How-
ver, detailed outcome analysis of PP using serial IVUS
maging has not been reported yet. Furthermore, the
ncidence and clinical impact of PP after DES implan-
ation has yet to be investigated.
Drug-eluting stents have been demonstrated to be effi-
acious in the treatment of coronary artery disease (4–9).
he efficacy of DES for the treatment of coronary artery
iseases in diabetic patients has been reported as well (10).
iabetic patients have more extensive, diffuse, and large
therothrombotic burden (11). However, data on the inci-
ence, IVUS characteristics, and clinical impact of PP in
iabetic patients are also lacking.
The aim of the present study was to evaluate the
ncidence and characteristics of PP as well as its clinical
mpact in diabetic patients treated with BMS and DES
sing 3-dimensional (3D) volumetric IVUS imaging.
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opulation. Two-hundred forty diabetic patients were en-
olled in the DIABETES (Diabetes and Sirolimus-Eluting
tent) I and II multicenter, prospective trials. Patients were
andomly assigned to receive BMS (BX Velocity/Sonic,
ordis, Johnson & Johnson) or sirolimus-eluting stents
SES) (Cypher, Cordis) in the DIABETES I trial (10). All
atients in the DIABETES II trial, which had the same
nclusion and exclusion criteria of DIABETES I study,
eceived paclitaxel-eluting stents (PES) (Taxus, Boston
cientific, Natick, Massachusetts) (12). Protocols were ap-
roved by the ethics medical committee of participating
nstitutions. All patients gave written informed consent. All
atients presented de novo coronary stenoses in 1 native
essel with symptoms or objective evidence of ischemia.
atients with 72 h of myocardial infarction, impaired left
entricular function (left ventricular ejection fraction
25%), stenoses located in saphenous bypass, arterial by-
ass grafting, unprotected left main, or severe hepatic or
enal disease were not included in the study. Intravascular
ltrasound was performed after intervention and/or at
-month follow-up in 168 diabetic patients with 205 lesions
patients/lesions: BMS: n  56/65; SES: n  57/69; PES:
 55/71, respectively). The cohort of patients assessed by
VUS represented 70% of the enrolled population, and 76%
f patients with follow-up assessments. Intravascular ultra-
ound analysis could not be performed in 9 cases with
omplete serial IVUS data because of poor image quality or
nadequate pullback speed. Intravascular ultrasound imaging
or serial comparison was not available either at baseline or
ollow-up in the remaining patients. Nevertheless, patients
ith serial IVUS analysis had similar baseline characteristics
nd clinical outcomes to those not evaluated by IVUS, not
ncluded in the present study. Angiographic restenosis and
tent thrombosis rates were evaluated at 9- and 12-month
ollow-up, respectively. Stent thrombosis was defined as an
cute coronary syndrome with angiographic documentation
f either vessel occlusion or thrombus within or adjacent to
previously successfully stented vessel. In the absence of
ngiographic confirmation, either acute myocardial infarc-
ion in the distribution of the treated vessel or sudden death
Abbreviations and Acronyms
BMS  bare-metal stents
CSA  cross-sectional area
DES  drug-eluting stents
DIABETES  Diabetes and Sirolimus-Eluting
Stent trial
DS  diameter stenosis
EEM  external elastic membrane
IVUS  intravascular ultrasound
MLD  minimal lumen diameter
PP  plaque prolapse
3D  3-dimensionalas considered as stent thrombosis. “Binary” restenosis was mefined as stenosis of more than 50% of the luminal
iameter in the target lesion at follow-up.
oronary stent procedure. Coronary angioplasty was per-
ormed according to standard practice. Predilation with the
se of a conventional balloon before stent implantation was
ptional. When multisegment or multivessel treatment was
erformed, all implanted stents had to be of the same type.
ll patients were treated with oral aspirin indefinitely (100
o 300 mg/daily) and clopidogrel (300 mg loading dose and
5 mg/daily maintenance dose for 1 year).
uantitative coronary angiographic analysis. The angio-
raphic analysis was blinded to treatment assignment by an
ndependent core laboratory (University of Florida Cardio-
ascular Imaging Core Laboratories, Jacksonville, Florida).
oronary angiograms obtained at 270 days of follow-up
ere analyzed with the use of a computer-based system (13).
he in-stent analysis encompassed only the segment cov-
red by each stent. The diameter stenosis (DS) and minimal
umen diameter (MLD) were measured before intervention
nd at follow-up. Balloon–artery ratio was measured by
tent size divided by reference vessel diameter.
VUS imaging protocol. Intravascular ultrasound images
ere acquired using a motorized pullback at a constant
peed of 0.5 mm/s, and volumetric quantification was
erformed. Images were recorded on high-resolution
-VHS tape for off-line analysis.
Qualitative and quantitative volumetric IVUS analyses
ere performed by an independent core laboratory (Univer-
ity of Florida Cardiovascular Imaging Core Laboratories,
acksonville, Florida). Quantitative 3D IVUS analysis was
erformed using a dedicated quantitative IVUS analysis
ystem (Pie Medical Imaging, Maastricht, the Netherlands)
14). The quantitative IVUS analysis system enables semi-
utomatic contour detection of the lumen, vessel, and stent
s well as quantitative analysis of their dimensions in
ongitudinal and cross-sectional views. Longitudinal recon-
tructed views at 5° increments are displayed. The resulting
ross-sectional Bezier contours can be visualized immedi-
tely superimposed on a running video loop and may be
dited manually. The mathematical description consists of a
onnected series of Bezier curves. Lumen, stent, and exter-
al elastic membrane (EEM) areas were measured along the
ntire target segment. This system has been validated and
sed in previous clinical studies (15). Volumes were deter-
ined from a summation of measured cross-sectional area
CSA) in all frames of pullback region based on Simpson’s
ule; between 200 and 1,000 CSA were measured per
egment. Mean areas were calculated as volumes divided by
egment length.
Plaque prolapse was defined as tissue extrusion through
he stent strut post-procedure, and the volume of PP was
utomatically calculated by subtracting lumen volume from
tent volume. Neointimal hyperplasia was defined as sub-
racting lumen volume from stent volume at follow-up.
elta volumes and mean areas were calculated as follow-up
inus post-values for EEM, lumen, and plaque.
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September 19, 2006:1139–45 Plaque Prolapse After Drug-Eluting StentsSerial IVUS analysis was performed for the stent segment
ncompassing PP (PP site). At follow-up, the stented
egment that matched the location of the site of PP
ost-procedure was selected for comparison. The remaining
tented segments without PP were also quantified by serial
VUS (non-PP sites).
tatistical analysis. Quantitative variables are presented as
ean  SD and categorical variables as percentages. Stu-
ent t test and one-way analysis of variance (ANOVA) were
sed to compare continuous variables. The paired-samples
tudent t test was used for within-group comparisons. The
air-wise comparison between groups was performed when
tatistical difference was detected by means of ANOVA.
ategoric variables were compared by means of the chi-
quare or Fisher exact test for comparisons between groups
Stat View, SAS Institute, Inc., Cary, North Carolina). No
djustments for multiple comparisons were made. Differ-
nces were considered statistically significant at p  0.05.
ESULTS
he baseline characteristics of the present study population
BMS: n  56; SES: n  57; PES: n  55) were similar to
hose of the overall DIABETES I and II study populations
Table 1) (10,12). There were 42 sites of PP (BMS  11,
ES  11, PES  20) in 34 stented segments (33 patients)
f 205 (16.6%; 95% confidence interval: 0.115 to 0.217)
esions. Baseline demographics between patients with and
ithout PP were similar, except for a higher prevalence of
en in the population with PP (Table 1). Plaque prolapse
as visible by angiography in 18 of the 34 lesions with PP
52.9%), and did not produce severe residual stenosis or
ignificant impairment in coronary flow. Angiographic and
linical outcomes of patients with angiographically visible
ersus non-visible PP were similar (data not shown). Fur-
her, there was no association between volume of PP and
utcomes (data not shown). There was no significant
ifference in the incidence of PP among the 3 stent types.
here was no significant difference in the volume of PP
mong the different stent groups (Fig. 1A). Plaque prolapse
as detected more frequently in the right coronary artery or
hronic total occlusion lesions. Conversely, PP was detected
ess frequently in the left anterior descending and left
ircumflex arteries (p  0.05) (Table 2).
There were no differences in mean stent length and size
etween lesions with versus without PP. Balloon–artery
atio was not significantly different between PP and non-PP
esions. Further, pre-procedure percent DS in PP lesions
as significantly higher, and MLD was significantly smaller
han in non-PP lesions. At follow-up, the incidence of stent
hrombosis and angiographic restenosis rate was not signif-
cantly different between PP and non-PP lesions (Table 2).
P versus non-PP sites. In lesions with PP, mean stent,
umen, and in-stent plaque (PP or neointimal hyperplasia)
reas at follow-up were not significantly different between
he sites of PP versus non-PP sites in each group (Table 3). Ta
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Plaque Prolapse After Drug-Eluting Stents September 19, 2006:1139–45ost-procedure plaque volume behind the stent struts was
lso measured. Plaque behind the stent may represent a
urrogate of pre-procedure plaque burden, because debulk-
ng was not performed in this study. There were no
ifferences in plaque burden behind the stent between PP
ites and non-PP sites.
The volume of in-stent tissue within the PP site increased
ignificantly after 9 months in the BMS group, but re-
ained unchanged after SES. A trend in tissue volume
ncrease in-stent was observed in the PES group (p 
.074). There was a different pattern in plaque volume
hanges within the PP site in the BMS and PES versus SES
Fig. 1).
In both BMS and PES, the mean plaque/tissue area
ithin the stent increased in both PP and non-PP sites at
ollow-up. However, delta plaque was similar between PP
nd non-PP sites in these groups. Indeed, there was
laque/tissue growth only in the non-PP sites in the SES
roup, although this was not statistically significant (Fig. 2).
t the site of segments with PP, the minimum lumen CSA
t follow-up was located within the PP site in 31.0% (BMS:
6.4%; SES: 27.3%; PES: 30.0%) (Table 3).
ISCUSSION
laque prolapse has been reported as an intraluminal tissue
atheroma or thrombus) protruding through the stent struts
1,16). Plaque prolapse within BMS has been found fre-
uently during IVUS-guided stenting. A single study eval-
ated the overall outcomes of patients with PP after BMS
2). However, detailed assessment of the vessel wall reaction
t the site of PP and the relative contribution of PP on
eointimal formation remained unknown. The present
tudy focused on diabetic patients who are known to have
arge atherothrombotic burden and may be more prone to
evelop PP after stenting. These patients have marked
roliferative response after stenting (17), which may amplify
he impact of PP. Our data suggest that PP is frequent in
igure 1. Change of tissue volume in the plaque prolapse sites within
ncreased as compared with that at post-intervention (PO) in both ba
endency to decrease in sirolimus-eluting stents (SES) (A). The delta v
hat in SES (B). p  0.05. Black bars  PO; hatched bars  FU.his patient population treated with new generation tubular mtents (DES and BMS), but the incidence of PP was not
igher than that previously reported. Whether the differ-
nce in stent design may account for these findings needs to
e further evaluated (2). In particular, the BX Velocity stent
s the platform in both SES and BMS groups.
We examined various factors to evaluate the conditions
hat predispose the occurrence of PP. Plaque prolapse was
etected more frequently in men, but other baseline char-
cteristics and stent dimensions were not associated with
P. There was a higher chance of PP after stenting severe
tenoses, chronic total occlusions, and right coronary artery
esions. The use of specific stent designs with larger surface
overage or debulking techniques to prevent PP in these
linical scenarios remains speculative and would require
roper evaluation in future studies. In addition, whether
otal occlusion in non-diabetic patients would also be
ssociated with a higher incidence of PP after stenting
emains to be investigated.
The apprehension that PP represents a milieu for
nhanced thrombus formation or intimal proliferation
as plagued cardiologists performing complex percutane-
us interventions for years. This is emphasized if one
onsiders the prothrombotic status that already charac-
erizes diabetic patients even when treated with antiplate-
et agents (18). In a recent IVUS evaluation on the causes
f BMS thrombosis, investigators listed PP as a potential
ontributor to thrombosis, although only 1 of 23 patients
nvestigated showed PP post-stenting (19). Finally, in-
reased neointimal hyperplasia has been associated with
he accumulation of circulating bone marrow– derived
mooth muscle cells (20). Whether PP sites would
rovide a medium for attachment and proliferation of
uch circulating cells remains unclear.
Particularly in the era of DES, PP may represent a source
f treatment failure as it may alter drug-elution profiles.
laque prolapse may also represent a source for thrombus
ccumulation in a potential highly thrombogenic environ-
us stent types. The volume of tissue within stent at follow-up (FU)
etal stents (BMS) and paclitaxel-eluting stents (PES), but there was
e of tissue within the stent in BMS or PES was significantly larger thanvario
re-m
olument. Indeed, impaired neointimal healing and stent
Table 2. Background and Outcome of PP
All (n  205) BMS (n  65) SES (n  69) PES (n  71)
PP Lesion Non-PP Lesion p PP Lesion Non-PP Lesion p PP Lesion Non-PP Lesion p PP Lesion Non-PP Lesion p
No. of lesions 34 171 9 56 9 60 16 55
Treated artery
LAD (n  89) 9 (10.1%) 80 (89.9%) 3 (33.3%) 28 (50%) 1 (11.1%) 27 (45%) 5 (31.2%) 25 (45.5%)
LCx (n  30) 3 (10.0%) 27 (90.0%) 0 (0%) 9 (16.1%) 1 (11.1%) 10 (16.7%) 2 (12.5%) 8 (14.5%)
RCA (n  86) 22 (25.6%) 64 (74.4%) 6 (66.7%) 19 (33.9%) 7 (77.8%) 23 (38.3%)* 9 (56.3%) 22 (40%)
Mean stent length (mm) 21.4  6.4 19.9  8.0 21.9  7.4 19.7  7.0 20.8  6.7 19.6  7.2 21.6  5.7 20.5  9.7
Mean stent size (mm) 3.1  0.4 3.0  0.4 3.2  0.5 3.0  0.5 2.9  0.5 2.9  0.3 3.2  0.4 3.0  0.4
Pre
%DS 74.2  20.0 61.7  13.5* 69.8  24.4 58.9  10.4 71.0  22.3 58.4  15.4 79.0  15.0 68.0  12.2
MLD (mm) 0.7  0.5 1.0  0.4* 0.7  0.6 1.0  0.4 0.8  0.7 1.0  0.4 0.5  0.4 0.9  0.4
CTO (n  18) 8 (44.4%) 10 (55.6%) 3 (33.3%) 4 (7.1%)* 2 (22.2%) 3 (5.0%) 3 (18.8%) 3 (5.5%)
Non-CTO (n  187) 26 (13.9%) 161 (86.1%) 6 (66.7%) 52 (92.9%) 7 (77.8%) 57 (95.0%) 13 (81.2%) 52 (94.5%)
Lesion length 15.6  4.5 15.1  7.9 14.6  4.8 15.9  8.0 15.5  5.0 13.7  6.7 16.3  4.5 15.6  8.9
Reference diameter (mm) 2.6  0.6 2.5  0.5 2.2  0.4 2.4  0.6 3.0  0.8 2.4  0.4 2.6  0.4 2.6  0.4
Overlaping (%) 14.7 8.2 33.3 12.5 22.2 5 0 7.3
Balloon–artery ratio 1.1  0.1 1.1  0.2 1.1  0.1 1.2  0.2 1.1  0.2 1.2  0.2 1.1  0.1 1.1  0.1
Post
%DS 14.5  6.7 16.6  9.7 21.1  12.5 14.8  6.7 14.5  16.2 15.1  7.6 12.7  9.9 13.6  6.1
MLD (in-stent) (mm) 2.3  0.4 2.3  0.4 2.0  0.5 2.2  0.4 2.4  0.4 2.2  0.4 2.4  0.3 2.4  0.4
MLD (in-lesion) (mm) 1.9  0.5 1.9  0.4 1.6  0.5 1.8  0.4 2.1  0.5 1.8  0.4 2.1  0.4 2.1  0.4
Angiographic evidence (%) 52.9 — 55.5 — 66.7 — 43.8 —
Follow-up
%DS 23.4  13.1 25.9  16.7 33.6  14.0 37.4  19.1 15.4  0.6 18.0  13.1 22.3  9.3 23.1  10.8
MLD (in-stent) (mm) 1.9  0.6 1.9  0.6 1.4  0.6 1.5  0.7 2.4  0.5 2.2  0.5 2.0  0.3 2.0  0.5
MLD (in-lesion) (mm) 1.7  0.6 1.7  0.6 1.3  0.6 1.4  0.6 2.1  0.4 1.8  0.5 1.8  0.4 1.7  0.5
Late loss (in-stent) 0.3  0.4 0.4  0.5 0.6  0.4 0.7  0.5 0.02  0.2 0.04  0.3 0.4  0.2 0.4  0.4
Late loss (in-lesion) 0.2  0.3 0.3  0.4 0.4  0.3 0.4  0.5 0.03  0.2 0.02  0.3 0.3  0.2 0.4  0.3
Restenosis (%) 14.7 11.7 44.4 25 0 3.3 6.3 7.3
Thrombosis (%) 0 0 0 0 0 0 0 0
Data are presented as mean  SD and frequency. *p  0.05; PP lesion vs. non-PP lesion.
BMS  bare-metal stent; CTO  chronic total occlusion; DS  diameter stenosis; LAD  left anterior descending; LCx  left circumflex; MLD  minimal lumen diameter; PES  paclitaxel-eluting stent; PP  plaque prolapse;
RCA  right coronary artery; SES  sirolimus-eluting stent.
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Plaque Prolapse After Drug-Eluting Stents September 19, 2006:1139–45hrombosis has been associated with prolapse of necrotic
ore between stent struts (21).
In the present study, serial IVUS evaluation of 42 sites of
P did not demonstrate increased neointimal proliferation
ompared with sites without PP in new generation tubular
tents (Fig. 2). Restenosis or thrombosis rates were similar
etween prolapsed lesions and non-PP lesions in each stent
roup. Further, angiographic in-stent late loss was similar
etween PP and non-PP sites in the BMS group. These
ndings corroborate a previous report on the lack of
ssociation between PP and restenosis in BMS (2). In the
resent study, a more detailed evaluation of vessel wall
esponse at the site of PP revealed a different pattern of
issue growth between SES and BMS or PES. Unlike BMS
nd PES, tissue volume in the PP sites of SES decreased.
elta plaque volume was significantly lower in the SES than
n BMS and PES (p  0.05) (Fig. 1).
Previous reports have suggested that SES could sup-
ress not only accumulation of medial smooth muscle
ells originated from the adjacent media but also accu-
ulation of circulating bone marrow– derived cells (22).
hether these findings may explain the different pattern
n plaque volume changes at the PP site between SES and
ES and BMS (Fig. 1) remains to be evaluated. It is
evertheless important to notice that similar patterns of
laque growth were observed in non-PP sites among the
tent groups.
The benign outcomes observed in the present study for
atients with diabetes mellitus who developed PP after
ES implantation is comforting, because the incidence
f this phenomenon will likely increase as more complex
nterventions are performed worldwide. Importantly, in
ur study population, no therapeutic measures were taken
n the presence of PP. The study findings may provide a
eference for cardiologists when facing this disturbing
henomenon, and suggest that non–flow-limiting PP
etected by either IVUS or angiography does not warrant
urther interventional maneuvers or unnecessary use of
able 3. Characterization of PP Site
BMS (n  11)
PP Site Non-PP
ost
Mean stent CSA (mm2) 10.6  3.1 10.2 
Mean lumen CSA (mm2) 10.0  2.9 10.2 
EEM CSA (mm2) 23.3  5.8 21.5 
Plaque behind the stent (mm2) 12.6  3.4 12.1 
ollow-up
Mean stent CSA (mm2) 10.5  2.7 10.0 
Mean lumen CSA (mm2) 7.2  3.3 6.8 
EEM CSA (mm2) 21.0  6.0 19.4 
Delta EEM CSA (mm2) 1.3  4.4 0.68 
Location of mimimum lumen CSA (%) 36.4 63.
ata are mean  SD. p value: no significance; PP site vs. non-PP site.
CSA  cross-sectional area; EEM  external elastic membrane; other abbreviatidditional devices. otudy limitations. The present study involved a large
ohort of patients with scheduled serial IVUS examination.
owever, our findings may not be applied to the general
opulation, particularly patients with bypass graft disease
nd acute ST-segment elevation myocardial infarction. In
hese clinical scenarios, careful differentiation between PP
nd new thrombus formation should be made, and the
ssociation between PP and clinical outcomes remains to be
nvestigated. Drop-outs and exclusions may have affected
he study findings, which mainly reflect outcomes of pa-
ients who were alive and without complications at the time
f follow-up examination.
Lack of pre-procedure IVUS data represents another
imitation of the present study. Thus, correlation between
laque characteristics and PP was not performed. How-
ver, plaque behind the stent provided an indirect assess-
ent of plaque burden, and allowed the evaluation of
he relationship between local plaque burden and sites
f PP.
Finally, this mechanistic and descriptive study may have
imited statistical power to detect small differences in
linical outcomes between patients with and without PP.
hus, our results should be interpreted with caution because
f potential type I error. However, the benign outcomes
bserved in our study population with PP, composed
xclusively of diabetic subjects who are known to have a
ore enhanced thrombotic milieu (18), are encouraging,
nd it is unlikely that different outcomes will be observed in
on-diabetic patients.
onclusions. The present study demonstrated a high in-
idence of PP in diabetic patients treated with BMS and
ES. The incidence of PP was similar between BMS and
ES, although there was a trend toward a higher incidence
f PP in patients treated with PES. Plaque prolapse was not
ssociated with exaggerated neointimal proliferation in ei-
her BMS or DES groups. Indeed, no neointimal prolifer-
tion was observed in the PP sites of patients treated with
ES. Plaque prolapse was not associated with increased risk
SES (n  11) PES (n  20)
PP Site Non-PP Site PP Site Non-PP Site
8.8  3.5 9.2  3.1 9.7  2.6 10.1  3.2
8.1  3.2 9.2  3.1 9.3  2.6 10.1  3.2
18.4  6.5 17.4  4.6 21.2  6.4 20.2  8.2
10.0  3.6 10.6  3.4 11.5  4.9 11.9  3.9
9.5  2.9 9.1  2.1 10.4  2.9 11.1  3.2
9.0  2.9 8.4  1.5 8.9  2.7 9.9  3.0
17.9  3.8 18.4  4.4 22.9  4.5 22.7  6.1
0.80  5.8 1.3  3.5 0.25  3.4 2.0  5.5
27.3 72.7 30.0 70.0
in Table 1.Site
3.6
3.6
6.5
4.4
3.0
3.2
5.8
3.3
6f stent thrombosis or restenosis.
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